S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.21%)
T   16.80 (+1.27%)
F   12.14 (+0.17%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.44 (+0.45%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NASDAQ:INDV

Indivior (INDV) Stock Price, News & Analysis

$21.28
-0.02 (-0.09%)
(As of 05:16 PM ET)
Today's Range
$20.87
$21.74
50-Day Range
$14.56
$21.30
52-Week Range
$14.38
$26.50
Volume
183,057 shs
Average Volume
102,420 shs
Market Capitalization
$2.93 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.00

Indivior MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
64.5% Upside
$35.00 Price Target
Short Interest
Healthy
0.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.94mentions of Indivior in the last 14 days
Based on 16 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
31.65%
From $1.39 to $1.83 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.20 out of 5 stars

Medical Sector

341st out of 939 stocks

Pharmaceutical Preparations Industry

155th out of 439 stocks


INDV stock logo

About Indivior Stock (NASDAQ:INDV)

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet. The company operates in approximately 40 countries worldwide. It has collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

INDV Stock Price History

INDV Stock News Headlines

Discover Lexagene - Open to Accredited Investors Only
Get access to significant growth potential in a rapidly scaling biopharma market
Indivior Q4 Revenue Surges
Indivior Announces Q4 / FY 2023 Financial Results
Indivior Announces Q4 / FY 2023 Financial Results
Indivior (INDV) Set to Announce Quarterly Earnings on Thursday
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Indivior PLC (INDV.L)
Indivior Announces Share Repurchase Program - Quick Facts
Indivior PLC (2IVB.MU)
Indivior PLC Ordinary Share INDV
See More Headlines
Receive INDV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Indivior and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/27/2023
Today
2/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:INDV
Employees
1,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.00
High Stock Price Target
$35.00
Low Stock Price Target
$35.00
Potential Upside/Downside
+64.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-53,000,000.00
Pretax Margin
-30.35%

Debt

Sales & Book Value

Annual Sales
$901 million
Cash Flow
$1.70 per share
Book Value
$0.37 per share

Miscellaneous

Free Float
N/A
Market Cap
$2.94 billion
Optionable
Not Optionable
Beta
0.41
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Mark Crossley
    CEO & Executive Director
  • Mr. Ryan Preblick
    CFO & Executive Director
  • Dr. Christian Heidbreder
    Chief Scientific Officer
  • Mr. Jason Thompson
    Vice President of Investor Relations
  • Ms. Cynthia Cetani
    Chief Integrity & Compliance Officer
  • Mr. Jeffrey W. Burris (Age 52)
    Chief Legal Officer
  • Mr. Jon Fogle
    Chief Human Resources Officer
  • Mr. Richard Simkin
    Chief Commercial Officer
  • Mr. Hillel West
    Chief Manufacturing & Supply Officer
  • Vishal Kalia
    Senior VP of US Treatment Access, Support Programs & Business Insights and Chief Strategy Officer














INDV Stock Analysis - Frequently Asked Questions

Should I buy or sell Indivior stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INDV shares.
View INDV analyst ratings
or view top-rated stocks.

What is Indivior's stock price target for 2024?

1 equities research analysts have issued 1-year target prices for Indivior's shares. Their INDV share price targets range from $35.00 to $35.00. On average, they expect the company's stock price to reach $35.00 in the next twelve months. This suggests a possible upside of 64.5% from the stock's current price.
View analysts price targets for INDV
or view top-rated stocks among Wall Street analysts.

How have INDV shares performed in 2024?

Indivior's stock was trading at $15.27 at the beginning of the year. Since then, INDV shares have increased by 39.4% and is now trading at $21.28.
View the best growth stocks for 2024 here
.

When is Indivior's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 25th 2024.
View our INDV earnings forecast
.

How were Indivior's earnings last quarter?

Indivior PLC (NASDAQ:INDV) posted its quarterly earnings data on Thursday, February, 22nd. The company reported $0.43 earnings per share for the quarter, beating analysts' consensus estimates of $0.28 by $0.15. The business earned $293 million during the quarter, compared to analysts' expectations of $260 million. Indivior had a positive trailing twelve-month return on equity of 370.37% and a negative net margin of 22.57%.

What guidance has Indivior issued on next quarter's earnings?

Indivior updated its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.2 billion-$1.3 billion, compared to the consensus revenue estimate of $1.2 billion.

Who are Indivior's major shareholders?

Indivior's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.28%), Goldman Sachs Group Inc. (3.23%), Barclays PLC (2.24%), Artemis Investment Management LLP (1.94%), Norges Bank (1.73%) and Premier Fund Managers Ltd (0.62%).

How do I buy shares of Indivior?

Shares of INDV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INDV) was last updated on 2/23/2024 by MarketBeat.com Staff